The design and synthesis of a novel piperidine series of farnesyltransferase (FTase) inhibitors with reduced potential for metabolic glucuronidation are described. The various substitution and exchange of the phenyl group at the C-2 position of the previously described 2-(4-hydroxy) phenyl-3-nitropiperidine 1a (FTase IC50= 5.4 nM) resulted in metabolically stable compounds with potent FTase inhibition (14a IC50= 4.3 nM, 20a IC50 ...
